This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Mark Hallett, M.D. – Federal Liaison to the Scientific Advisory Board
Dr. Hallett is the Chief of the Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
He trained at Harvard Medical School, NIH, Massachusetts General Hospital and the Institute of Psychiatry in London.
From 1976 to 1984, Dr. Hallett was the Chief of the Clinical Neurophysiology Laboratory at the Brigham and Women’s Hospital and rose to Associate Professor of Neurology at Harvard Medical School.
From 1984, he has been at the National Institute of Neurological Disorders and Stroke where he also served as Clinical Director of NINDS until July 2000.
He is past President of the American Association of Electrodiagnostic Medicine and the International Parkinson and Movement Disorder Society, past Vice-President of the American Academy of Neurology, and current President of the International Federation of Clinical Neurophysiology.
His work mainly deals with principles of motor control and the pathophysiology of movement disorders, and he has been a leader in the use of transcranial magnetic stimulation for these purposes.